Most phase 2/phase 3 oncology clinical trials do not report American Indian or Alaska Native and Native Hawaiian or Other Pacific Islander racial categories in their studies, according to findings published in JAMA Health Forum. Additionally, information on Black or African American as well as Hispanic patients continues to lag.
CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO
CHICAGO — Isatuximab combined with a standard first-line treatment regimen significantly reduced the risk for disease progression and death in certain older individuals with multiple myeloma, results from a randomized phase 3 study showed.Additionally, patients with newly diagnosed, transplant-ineligible disease treated in the isatuximab (Sarclisa, Sanofi) arm of the IMROZ trial had
CHICAGO — Glucagon-like peptide-1 receptor agonists lowered the risk for obesity-related cancers compared with bariatric surgery among individuals with a BMI of at least 35, according to data presented at ASCO Annual Meeting. Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) conferred a greater risk reduction in all-cause mortality, despite inferior weight loss results
CHICAGO — An AI-guided navigation workflow helped identify patients earlier in the diagnostic timeline than the traditional cancer referral process while reducing times to biopsy, follow-up and treatment initiation, study results showed. Researchers, who presented their findings at ASCO Annual Meeting, also noted that implementation of the AI-guided navigation workflow increased patient